Upon the completion of a transition services agreement, Biocon Biologics will assume responsibility for commercial, regulatory and other related services.
The investment from 5th Century Partners will be used by the brand to help fund its ambitions, domestic and global expansions and new product innovations.
WBA's fourth quarter sales from continuing operations decreased 5.3% from the year-ago quarter to $32.4 billion, a decrease of 3.2% on a constant currency basis.